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A B S T R A C T
High doses of antipsychotics have been associated with loss in cortical and total gray matter in schizophrenia.
However, previous imaging studies have not taken benzodiazepine use into account, in spite of evidence sug-
gesting adverse effects such as cognitive impairment and increased mortality. In this Northern Finland Birth
Cohort 1966 study, 69 controls and 38 individuals with schizophrenia underwent brain MRI at the ages of 34 and
43 years. At baseline, the average illness duration was over 10 years. Brain structures were delineated using an
automated volumetry system, volBrain, and medication data on cumulative antipsychotic and benzodiazepine
doses were collected using medical records and interviews. We used linear regression with intracranial volume
and sex as covariates; illness severity was also taken into account. Though both medication doses associated to
volumetric changes in subcortical structures, after adjusting for each other and the average PANSS total score,
higher scan-interval antipsychotic dose associated only to volume increase in lateral ventricles and higher
benzodiazepine dose associated with volume decrease in the caudate nucleus. To our knowledge, there are no
previous studies reporting associations between benzodiazepine dose and brain structural changes. Further
studies should focus on how these observations correspond to cognition and functioning.
1. Introduction
Progressive changes in the brain structures of individuals with
schizophrenia compared to healthy controls have been reported espe-
cially in frontal and temporal lobes, anterior cingulate, hippocampus,
amygdala, thalamus and insula (Shepherd et al., 2012; Torres et al.,
2013). The possible effects of antipsychotics on brain structure and
functioning have been of intensive study in recent years (Andreasen
et al., 2013; Ho et al., 2011; Radua et al., 2012), and a meta-review
concluded that previous comparisons between healthy controls and
people with schizophrenia may be, at least partly, confounded by the
effects of medication (Shepherd et al., 2012). However, in spite of
several reviews and meta-analyses (Fusar-Poli et al., 2013; Roiz-
Santiáñez et al., 2015; Vita et al., 2015) on the association between
antipsychotics and brain volume changes, the results are inconclusive
with a need for further studies.
Many imaging studies in schizophrenia are conducted in the early
phase of the illness, mostly during the first episode, when the possible
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long-term effects of medications may not yet be noticeable. However,
studies in rodents suggest that the effects of antipsychotics on the brain
are evident also at later stages of the treatment (Terry et al., 2008,
2007a, 2007b; Terry and Mahadik, 2007). Some studies focus on pa-
tients drawn from clinics serving chronic patients, where the patients
might be on average sicker and therefore not representative of the great
variety of different stages of illness found in entire population suffering
from the disease. Clinical trials with strictly defined medication doses
over years of follow-up are hard to conduct, and few include imaging
measures in their protocol. Therefore the data from naturalistic settings
are crucial when examining potential long-term effects and adverse
effects of antipsychotic treatment (Wang et al., 2011).
Pharmacological treatment of schizophrenia is not limited to anti-
psychotic medication. Benzodiazepines are commonly used in schizo-
phrenia as sedatives or anxiolytics and to reduce aggressiveness and
ease agitation. In schizophrenia, benzodiazepine use has been asso-
ciated with increased risk of mortality even after controlling for po-
tential confounders (Fontanella et al., 2016) and, in general, benzo-
diazepine use has been associated with not only increased mortality
(Tiihonen et al., 2016) but also cognitive impairment (Baandrup et al.,
2017; Barker et al., 2005, 2004a, 2004b). Although the mechanism of
these effects is unknown, adverse effects on brain health such as ac-
celerated ageing (Koutsouleris et al., 2014; Schnack et al., 2016), or
individually varying decreases in brain volume (Schnack et al., 2016),
are possible candidate mechanisms that merit investigation. In the
general population, approximately 3% use benzodiazepines over 6
months, which is defined as long-term treatment (Kurko et al., 2015).
Recently chronic benzodiazepine use has been associated with decrease
in brain plasticity in mice (Curto et al., 2016), but there are no modern
structural imaging studies on benzodiazepine effects on the human
brain. Previous studies have used computed tomography (CT) to study
the effect of benzodiazepine use mainly on ventricular enlargement
(Busto et al., 2000; Lader et al., 1984; Moodley et al., 1993; Perera
et al., 1987; Schmauss and Krieg, 1987; Uhde and Kellner, 1987), but to
our knowledge there are no previous MRI studies on benzodiazepine
effects on brain structures in schizophrenia (or other conditions).
Because antipsychotic medication is the key treatment in schizo-
phrenia and other psychoses, it is highly important to take possible
confounding factors into account when studying potentially harmful
effects of antipsychotic medications. Important confounding factors are
for example illness duration and severity, age, sex, and other long-term
medications. Nevertheless, only a few previous studies on long-term
follow-ups have taken into account illness severity measures when
analyzing antipsychotic effects on brain structures (Huhtaniska et al.,
2017).
In this study our aim was to analyze, in a population-based sample
of schizophrenia cases with illness duration on average of 10 years at
baseline, whether a nine-year scan-interval antipsychotic or benzodia-
zepine dose would have an effect on brain structural changes. This is
the first longitudinal MRI study that we are aware of to investigate the
effects of benzodiazepines on brain structure in schizophrenia and to
examine the effects of antipsychotic medication on brain structure in
schizophrenia whilst controlling for benzodiazepine use.
2. Methods
2.1. Study sample
This study is based on an unselected, general population birth co-
hort called The Northern Finland Birth Cohort 1966 (NFBC1966). The
Ethical Committee of the Northern Ostrobothnia Hospital District has
approved the NFBC1966 project and keeps its study design under
continuous review. The sample collection is described in more detail in
our previous publications using a partly overlapping sample (Guo et al.,
2015; Veijola et al., 2014) and in the Supplementary Methods.
Forty-five individuals with schizophrenia spectrum disorder and 77
non-psychotic controls participated in both baseline and follow-up
studies when the participants were approximately 34 and 43 years old.
At baseline the diagnoses were validated (Isohanni et al., 1997;
Moilanen et al., 2003) using the Structured Clinical Interview for DSM-
III-R (SCID-I; Spitzer et al., 1989) criteria and anamnestic information
including individual hospital medical records. The original diagnoses
were confirmed at the follow-up using Structured Diagnostic Interview
for DSM-IV (First et al., 2002) and information from medical records.
SCID-I was also completed for controls at both time points.
For seven participants with schizophrenia spectrum disorder and
seven controls MRI data were incomplete (scans missing or too poor
quality at either time-point). One of the controls had a psychotic epi-
sode during the follow-up period according to the Care Register for
Health Care (CRHC) and was not included in the final study group.
Therefore, the final schizophrenia spectrum group included 38 parti-
cipants and the control group 69 participants. The specific diagnoses for
the schizophrenia spectrum group were schizophrenia (n = 33), schi-
zophreniform disorder (n = 1), schizoaffective disorder (n = 3) and
delusional disorder (n = 1). Hereafter the term schizophrenia is used to
refer to schizophrenia and other schizophrenia spectrum disorders. The
sample collection is described in more detail in Supplement Fig. 1 and
in Supplementary Methods.
In schizophrenia group the participants did not differ statistically
significantly from the non-participants and are representative of the
entire schizophrenia population in NFBC1966 regarding age, sex and
educational level. In the control group, the participants’ level of edu-
cation was higher than of the non-participants (Veijola et al., 2014).
2.2. Data on medication
Lifetime psychiatric medication use was collected using all available
medical records (hospital and out-patient care case notes), an interview
conducted at both baseline and follow-up, and the register of the
Finnish Social Insurance Institution on psychoactive medications con-
sumed during 1997 (Husa et al., 2014; Veijola et al., 2014). The med-
ical records were acquired on the basis of information concerning the
subjects’ treatment facilities, which we received from the CRHC. If the
subject had no information in the CRHC, we requested medical records
from the outpatient facilities of the subjects’ area of residence. Parti-
cipants in this study had given their permission to collect medical re-
cords by signing the written informed consent. We had permission for
collecting the data from the Ministry of Social Affairs and Health.
All medical records were reviewed to record the name of the drug,
dose and time period the medication had been used. Drugs were cate-
gorized by using the Anatomical Therapeutic Chemical (ATC) classifi-
cation system (WHO, 2010). Antipsychotics included classes N05A
(antipsychotics) and Pertriptyl (N06CA01 combination medicine in-
cluding perphenazine). Benzodiazepines included ATC classes N05BA
(anxiolytics, benzodiazepine derivatives), N05CD (hypnotics and se-
datives, benzodiazepine derivatives), and N05CF (hypnotics and seda-
tives, benzodiazepine-related drugs). For antipsychotic medication, the
information was used to calculate the cumulative doses of lifetime and
interscan interval antipsychotic doses expressed as dose-years of a daily
dose of 100 mg chlorpromazine (CPZy) using several sources, see
Moilanen et al. (2015) for details. For benzodiazepines, the information
was used to calculate the defined daily doses (DDD) (Nykänen et al.,
2016; Rissanen et al., 2015) and these were then expressed as benzo-
diazepine dose-years (BZDy). One BZDy is equivalent to the amount of
benzodiazepine medication, which a person would use if the daily dose
was 1 DDD and the duration of treatment would be one year. All the
used medications are listed in Supplement Table 1.
2.3. Covariates and background variables
Onset age of the illness was ascertained from medical records and it
was defined as the age of first evident psychotic symptoms. Clinical
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symptoms in participants with schizophrenia at baseline and follow-up
were examined using the Positive and Negative Syndrome Scale
(PANSS) (Kay et al., 1987). In the baseline study, the PANSS was
measured based on the SCID I -interview and general psychiatric in-
terview, while in the follow-up study PANSS was defined using a spe-
cific PANSS interview. The number of hospital days during the follow-
up was collected from the CRHC. We used hospital treatment days as an
additional measure of illness severity, because it is the only available
variable that reflects the illness severity status over the entire follow-up
period. Remission was assessed using the Andreasen criteria (Andreasen
et al., 2005), but the symptoms were only required not to be present
during the period of one week before the assessment, and no duration
criteria was used since PANSS was done only once at baseline and
follow-up. At follow-up, we gathered information on medication related
side-effects, such as extrapyramidal symptoms or weight gain, using the
LUNSERS scale (Day et al., 1995).
2.4. MRI methods
The participants were scanned with the same 1.5 T GE Signa
scanner (General Electric, Milwaukee, Wisconsin) at both baseline and
follow-up at the Oulu University Hospital. At baseline T1-weighted
high-resolution three dimensional spoiled gradient echo (3D SPGR)
images were acquired in the coronal plane covering the whole brain
(slice thickness 1.5 mm; in-plane resolution matrix size 256×256;
voxel size 1.5 mm × 1 mm × 1 mm; repetition time 35 ms; echo time
5 ms; flip angle = 35). Prior to the follow-up imaging the scanner was
up-graded into HDxt with a new gradient system and parallel image
data acquisition with an 8 channel receiving coil. At follow-up, the T1
weighted images were acquired with a 3D fast spoiled gradient echo
(FSPGR) sequence (slice thickness = 1 mm; in-plane resolution matrix
size 256 × 256; voxel size 1 mm3; repetition time 12.576 ms; echo time
5.3 ms; flip angle = 20).
2.5. MRI data processing
To extract the brain tissue volumes from the MRI images we used an
online automated MRI brain volumetry system volBrain (http://
volbrain.upv.es/) (Manjón and Coupé, 2016). VolBrain segments the
MRI into 15 different brain tissue classes or structures (white matter
(WM), gray matter (GM), cerebrospinal fluid (CSF), brain (WM+GM),
intracranial cavity, cerebrum, cerebellum, brainstem, lateral ventricles,
caudate, putamen, thalamus, globus pallidus, hippocampus, amygdala,
accumbens) separated in right and left if applicable. Details on the
image processing pipeline are provided in Supplementary Methods. In
this study we focused mainly on subcortical structures.
Since there are many concerns regarding the methodology and re-
plicability of measures in longitudinal MRI studies, and as we had a
scanner update during the follow-up, we performed a calibration scan
inviting 15 controls to be scanned with both used protocols during the
same day to assess the possible effect of the scanner update on our
measurements. With the help of these calibration-scans, we measured
the inter-scan reliability rates for each extracted brain structure volume
and excluded the structures with single measures intraclass correlation
poorer than 0.90. For more information on the calibration scan and
reliability measures, see Supplementary Methods and Supplement
Table 2.
We calculated the annual change of each studied brain region using
the total change during the follow-up and the length of follow-up for
each individual.
2.6. Statistical analyses
The brain structural MRI changes were examined in 10 different
measures based on the interest in subcortical structures and our inter-
scan reliability measures. These areas were: total brain, total gray
matter (GM), cerebrum, cerebral GM, lateral ventricles, caudate nu-
cleus, putamen, thalamus, hippocampus, and nucleus accumbens. We
analyzed differences between subjects with schizophrenia and non-
psychotic controls and associations between medication doses during
the scan interval and brain areas in the schizophrenia group. We ap-
plied a logarithmic transformation to medication data and the number
of hospital days during the follow-up due to skewness of these variables
and used them as continuous variables in analyses.
All analyses were made by linear regression with sex and baseline
ICV as covariates. In medication analyses, we added the average PANSS
score between the two time points and hospital treatment days during
the follow-up as additional covariates. We also added benzodiazepine
BZDy as a covariate in analyses of CPZy, and vice versa.
As post hoc analyses we divided the schizophrenia group in to 4
subgroups based on median doses of antipsychotics and benzodiaze-
pines and looked at the subgroup findings in areas that were statisti-
cally significant in the original analyses. Based on the antipsychotic/
benzodiazepine medication dose, the 4 subgroups were high/high (n =
12), high/low (n = 7), low/high (n = 6) and low/low (n = 13). We
tested whether there would be an interaction between antipsychotic
and benzodiazepine status (high/low) in the brain areas with statisti-
cally significant findings. We also did additional analyses to see whe-
ther alcohol use disorder diagnosis would affect the brain structural
changes in the schizophrenia group.
The analyses were performed using IBM SPSS Statistics version 23
using p< 0.05 as a limit for statistical significance.
3. Results
3.1. Characteristics of the sample
The characteristics of the schizophrenia group are described in
Table 1. In schizophrenia group the number of males was 21 (54%), age
at baseline was on average 33.7 years and the length of follow-up was
9.1 years. At baseline 13 (34%) subjects were in remission and at
follow-up 12 (32%). Fourteen (37%) subjects were on disability pension
at baseline and the average PANSS score between the two time points
was 61.4 (SD 20.7).
Schizophrenia cases showed statistically significant decreases in the
volumes of total brain (t=−2.27, p= 0.025), cerebrum (t=−0.38, p
= 0.019), caudate nucleus (t = −4.05, p<0.0001), thalamus (t =
−0.14, p = 0.035) and hippocampus (t = −0.023, p = 0.028) when
compared to controls. All results on case control differences are pre-
sented in Supplement Table 3 and the average volume change in cases
and controls is presented in Supplement Table 4.
3.2. Medication use characteristics
Medication use characteristics of the schizophrenia group are de-
scribed in Table 2. Before baseline 37 (97%) schizophrenia subjects had
been medicated with antipsychotics. All of them had used typical an-
tipsychotics and 20 (53%) had used atypical antipsychotics. The mean
cumulative dose of antipsychotics by baseline was 27.6 (SD 34.9) CPZy.
During the follow-up 34 (90%) subjects used antipsychotics. Five
subjects (13%) used only typical antipsychotics and six subjects (15%)
used only atypical antipsychotics. Twenty-three (61%) subjects used
both typical and atypical antipsychotics during the follow-up. The mean
dose of antipsychotics during the follow-up for all medicated subjects
was 28.5 (SD 24.8) CPZy, for subjects using only typical antipsychotics
7.7 (SD 9.3) CPZy, and for subjects using only atypical antipsychotics
19.0 (SD 18.7) CPZy.
Before baseline 36 (95%) subjects had used benzodiazepines. Five
(14%) subjects had used benzodiazepines only irregularly (prescribed
to be taken only when needed). The mean cumulative dose of benzo-
diazepines by baseline was 3.6 (SD 4.3) BZDy. During the follow-up 30
(79%) subjects used benzodiazepines. Ten (33%) subjects used
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benzodiazepines only irregularly during the follow-up. The mean dose
during the follow-up was 6.7 (SD 8.2) BZDy.
3.3. Association between cumulative antipsychotic dose during the follow-up
and brain changes
Higher scan interval CPZy associated with increased lateral ven-
tricle volumes (b = 0.46, p = 0.012) and decrease in volumes of total
GM (b = −0.38, p = 0.012), cerebral GM (b = −0.39, p = 0.012),
thalamus (b = −0.34, p = 0.030), hippocampus (b = −0.34, p =
0.040) and nucleus accumbens (b=−0.38, p= 0.018). After adjusting
analyses with benzodiazepine BZDy and PANSS average score, only the
finding regarding lateral ventricles remained statistically significant (b
= 0.50, p = 0.028). Even when hospital days during the follow-up
were added to the model, the association still remained (b= 0.487, p=
0.035).
On the brain areas where PANSS average score during the follow-up
was statistically significantly associated with brain structure volume
changes (total GM, cerebral GM and nucleus accumbens), the effect size
of PANSS was roughly the same as the effect size of CPZy on those brain
areas. The effect of onset age was also roughly the same as the effect of
CPZy on the same areas. All results regarding all covariates and brain
volumes are presented in Table 3. Tables 4.1 and 4.2 present the results
of effects of CPZy and BZDy in adjusted analyses.
3.4. Association between cumulative benzodiazepine dose during the follow-
up and brain changes
Higher scan interval benzodiazepine BZDy associated with increase
in the volume of the lateral ventricles (b = 0.35, p = 0.037) and de-
crease in the following volumes: total brain (b = −0.35, p = 0.037),
cerebrum (b = −0.32, p = 0.048), caudate nucleus (b = −0.49, p =
0.002), thalamus (b = −0.36, p = 0.033) and nucleus accumbens (b =
−0.40, p = 0.018). After adjusting for CPZy and PANSS average score
only the finding regarding the caudate nucleus remained statistically
significant (b = −0.42, p = 0.029).
3.5. Post hoc analyses
In post hoc analyses, the mean volumes for lateral ventricle volume
change was 11.9 in the high antipsychotic/high benzodiazepine group,
6.7 in high antipsychotic/low benzodiazepine group, 4.7 in low anti-
psychotic/high benzodiazepine group and 2.7 in low/low group. The
mean volumes for caudate nucleus change were −0.33 in high/high
group, −0.08 in high/low group, −0.11 in low/high group and 0.16 in
low/low group. Analysis of variance documented a main effect of an-
tipsychotic dose in the lateral ventricles (F1,34 = 5.5, p = 0.025), with
no main effect of benzodiazepine dose (F1,34 = 2.28, p = 0.14) and no
interaction (F1,34 = 0.46, p = 0.5). In the caudate, there was a main
effect of benzodiazepines (F1,34 = 4.83, p = 0.035), a marginal main
effect of antipsychotic dose (F1,34 = 3.97 p = 0.054) and no interaction
(F1,34 = 0.001 p = 0.971).
In analyses of association between alcohol use disorder diagnosis
Table 1
Characteristics of the schizophrenia group (N = 38).
N %
Gender Male/Female 21/17 55.3/44.7
Educational level at baseline
Basic (< 9 years) 20 52.6
Secondary (9–12 years) 9 23.7
Tertiary (> 12 years) 9 23.7
Marital status at baseline
Married/cohabited 11 28.9
Not married/cohabited 27 71.1
Working status at baseline
Disability pension 14 36.8
Employed 14 36.8
Other (unemployed, not in working life due
to other reasons than disability pension)
10 25.6
Comorbid diagnose of alcohol use
disorder at baseline
No /Yes 29 / 9 76.3 / 23.7
Number of patients hospitalized before
baseline
37 97.4
Remission at baseline/follow-up 13/12 34.2/31.6
Extrapyramidal symptoms at follow-up 5 13.2
Weight gain due to medication 3 7.9
Clozapine use during the follow up 7 18.4
Diagnosis
Schizophrenia 33 86.8
Undifferentiated type 18 54.5a
Paranoid type 6 18.2a
Disorganized type 7 21.2a
Residual type 2 6.0a
Schizophreniform disorder 1 2.6
Schizoaffective disorder 3 7.9
Delusional disorder 1 2.6
Mean (SD) Range
Age of onset (years) 23.1 (4.4) 16.7–31.0
Age at baseline (years) 33.7 (0.7) 32.6–35.4
Age at follow-up (years) 42.8 (0.5) 41.8–44.0
Follow-up length (years) 9.1 (0.6) 7.5–10.2




Average total PANSS score 61.4 (20.7) 30–95
Number of hospital treatment days until
baseline
514.4 (892.6) 0–4703
Number of hospital treatment days during
the follow-up
86.3 (129.1) 0–594
Number of hospital treatment days in
hospitalized patients during the
follow-up
131.1 (139.9) 2–594
a Of the 33 schizophrenia cases.
Table 2
Medication use characteristics of schizophrenia cases (N = 38).
N (%) Mean dose
(Median)
IQR
Use of antipsychotics before baseline
in CPZy
Use of antipsychotics 37 (97.4) 27.6 (14.0) 4.6–44.3
Use of typical antipsychotics 37 (97.4) 21.6 (8.7) 2.6–30.4
Use of atypical antipsychotics 20 (52.6) 11.0 (5.9) 1.6–11.0
Use of clozapine 9 (23.7) 16.7 (9.8) 1.6–29.8
Use of antipsychotics during the
follow-up in CPZy
Use of antipsychotics 34 (89.5) 28.5 (20.8) 8.8–43.7
Use of typical antipsychotics 28 (73.7) 9.4 (6.1) 0.5–14.3
Use of atypical antipsychotics 29 (76.3) 24.3 (20.3) 6.4–38.7
Using typical antipsychotics only 5 (13.2) 7.7 (4.5) 0.1–16.8
Using atypical antipsychotics only 6 (15.8) 19.0 (12.5) 4.3–37.7
Using both typical and atypical
antipsychotics
23 (60.5) 35.5 (38.2) 11.6–48.9
Use of clozapine 7 (18.4) 3.2 (3.6) 2.0–3.8
Use of benzodiazepines in BZDy
Use of benzodiazepines before baseline
scan
36 (94.7) 3.6 (2.5) 0.3–4.8
Use of benzodiazepines only irregularly
before baseline scan
5 (13.8) 1.1 (0.6) 0.3–2.2
Use of benzodiazepines during the
follow-up
30 (78.9) 4.1 (3.3) 0.8–5.1
Use of benzodiazepines only irregularly
during the follow-up
10 (33.3) 1.6 (1.1) 0.7–3.3
Use of both antipsychotics and
benzodiazepines during the
follow-up




IQR = interquartile range, CPZy = antipsychotic dose years in chlorpromazine equiva-
lents, BZDy = benzodiazepine dose years in defined daily dose.
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and brain structural change in schizophrenia there were no statistically
significant results, see Supplement Table 5 for details.
4. Discussion
4.1. Main results
In this study we found that in subjects with schizophrenia, higher
antipsychotic medication dose during the follow-up related to increase
in lateral ventricular volume when taking into account illness severity
measures and benzodiazepine dose. Higher benzodiazepine dose
associated with caudate volume reduction after adjusting for average
PANSS score and antipsychotic dose.
4.2. Antipsychotic use and brain volume change
In a partly overlapping NFBC1966 sample we have found that in
schizophrenia, a higher amount of antipsychotic medication over the 9-
year follow-up (between ages 34 and 43 years) predicted larger total
brain volume loss (Veijola et al., 2014). Consistent with those results,
here, using a different image analysis method, we noted associations
between antipsychotic medication exposure and decrease in total grey
Table 3
Associations between medication variables and other covariates and change of brain volumes between the age of 34 years and 43 years in schizophrenia. Sex and ICV at the age of 34
years are covariates in all analyses. Statistically significant (p< 0 05) findings are in bold.
Brain area CPZy BZDy PANSS Age of illness onset Number of hospitalization days
Total Brain b = −0.269 b = −0.346 b = −0.088 b = 0.061 b = −0.342
p = 0.088 p = 0.037 p = 0.590 p = 0.713 p = 0.027
Total GM b = −0.380 b = −0.151 b = −0.373 b = 0.429 b = −0.181
p = 0.012 p = 0.367 p = 0.013 p = 0.005 p = 0.242
Cerebrum b = −0.261 b = −0.324 b = −0.083 b = 0.046 b = −0.307
p = 0.092 p = 0.048 p = 0.607 p = 0.779 p = 0.045
Cerebrum GM b = −0.387 b = −0.152 b = −0.370 b = 0.414 b = −0.182
p = 0.012 p = 0.376 p = 0.015 p = 0.009 p = 0.250
Lateral ventricles b = 0.458 b = 0.355 b = 0.212 b = −0.301 b = 0.312
p = 0.003 p = 0.037 p = 0.211 p = 0.069 p = 0.050
Caudate b = −0.294 b = −0.489 b = −0.250 b = 0.152 b = −0.394
p = 0.062 p = 0.002 p = 0.117 p = 0.357 p = 0.012
Putamen b = −0.303 b = −0.266 b = −0.250 b = 0.283 b = −0.343
p = 0.074 p = 0.144 p = 0.154 p = 0.107 p = 0.046
Thalamus b = −0.344 b = −0.360 b = −0.257 b = 0.197 b = −0.384
p = 0.030 p = 0.033 p = 0.121 p = 0.238 p = 0.013
Hippocampus b = −0.340 b = −0.184 b = −0.163 b = 0.140 b = −0.566
p = 0.040 p = 0.306 p = 0.337 p = 0.424 p = 0.0003
Accumbens b = −0.378 b = −0.404 b = −0.369 b = 0.497 b = −0.312
p = 0.018 p = 0.018 p = 0.023 p = 0.002 p = 0.055
CPZy = antipsychotic dose years in chlorpromazine equivalents during follow-up, BZDy = benzodiazepine dose years in defined daily dose during follow-up, ICV = intracranial volume,
GM = grey matter, b = standardized beta, PANSS = The average score of Positive and Negative Syndrome Scale (PANSS) total score at 34 years and 43 years.
Table 4.1
Associations between independent variables and brain structural change during the follow up, and statistically significant associations between antipsychotic dose years, benzodiazepine
dose years, and PANSS average score and brain structural changes in the same model. ICV and sex as covariates in all analyses. Statistically significant (p<0 05) findings are in bold.
Brain area CPZy BZDy PANSS CPZy, BZDy and PANSS in the same model







b = -0.233 p = 0.252







b = -0.240 p = 0.252







b = -0.210 p = 0.296







b = -0.250 p = 0.242







b = 0.502 p = 0.028
BZDy
b = 0.125 p = 0.517







b = -0.422 p = 0.029














b = -0.185 p = 0.419
BZDy
b = -0.241 p = 0.233







b = -0.332 p = 0.176







b = -0.352 p = 0.727
BZDy
b = -0.244 p = 0.270
CPZy = antipsychotic dose years in chlorpromazine equivalents during follow-up, BZDy = benzodiazepine dose years in defined daily dose during follow-up, ICV = intracranial volume,
GM = grey matter, b = standardized beta, PANSS = The average score of Positive and Negative Syndrome Scale (PANSS) total score at 34 years and 43 years, n.s. = non-significant.
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matter (with a marginal effect on total brain volume). These effects
were attenuated when we controlled for potential confounding factors
including benzodiazepine use, which we and others did not control for
in previous studies. However, the association we observed here be-
tween antipsychotic medication exposure and lateral ventricular
change was robust to controlling for illness severity and benzodiazepine
use. In our previous studies in this sample using the FSL tool SIENA to
examine movement over time (atrophy) at the brain edge, we noted an
association between higher antipsychotic medication dose and lateral
ventricular volume increase (Veijola et al., 2014), and periventricular
brain volume reductions at the fourth ventricular edge (Guo et al.,
2015). When viewing these studies using different methods together, it
appears in our sample that there is a consistent association between
antipsychotic medication exposure and ventricular volume change.
Furthermore, we find that antipsychotic dose predominantly relates to
increase in lateral ventricle volume independent of benzodiazepine
dose. However, we recognize that not all other studies have noted si-
milar effects (Ho et al., 2011; Saijo et al., 2001; Puri et al., 2001).
We have also studied cognition in this sample in relation to medi-
cation. Higher dose-years of antipsychotics associated with decline in
verbal learning and memory between ages 34 and 43 years (Husa et al.,
2014). High lifetime dose and antipsychotic polypharmacy associated
also with poorer outcomes in schizophrenia at the age of 43 years
(Moilanen et al., 2015). These results are consistent with the possibility
that long-term antipsychotic medication has some adverse effects on
the brain, although it remains possible that residual confounding may
be responsible for these associations. For example, although we adjust
for illness severity in our sample, we did not have information on se-
verity of illness (e.g. symptoms) for the entire follow-up period. Patients
with the most severe illness may be the ones who are prescribed the
most medication by doctors attempting to regain symptom control, but
it may be that a more severe disease process results, through unknown
mechanisms unrelated to medication, in the most cognitive decline and
the most progressive brain atrophy.
The potential antipsychotic effect on brain structures in schizo-
phrenia was suggested in the 1970's by Marsden (Marsden, 1976) in
response to the report on lateral ventricle increase in schizophrenia by
Johnstone et al. (1976). Since then the issue has been raised again in
the 2000's as the effects of second-generation antipsychotics on the
brain started to be studied and compared with traditional first-gen-
eration antipsychotics (e.g. Crespo-Facorro et al., 2008; Lieberman
et al., 2005; Mamah et al., 2012; Roiz-Santiáñez et al., 2012). Animal
studies have examined different antipsychotic agents and treatments,
and the results suggest that antipsychotics may have effects on brain
structures even when illness related confounding factors present in
human studies are excluded (Dorph-Petersen et al., 2005; Vernon et al.,
2014, 2011).
The possible mechanism behind antipsychotic-related structural
brain changes is not clear. In striatal areas antipsychotics may increase
striatal metabolism as a consequence of increased firing rates induced
by antipsychotic induced presynaptic D2 blockade, possibly leading to
increased volumes (Buchsbaum et al., 1992). This has been associated
especially to typical antipsychotic use, whereas some studies have
found atypical antipsychotics to even reverse this effect after switching
(Lang et al., 2004; Scheepers et al., 2001). However, a systematic re-
view on antipsychotic monotherapy effects in basal ganglia reported
that no studies found typical antipsychotics to induce basal ganglia
volume increases, but atypical antipsychotics have been associated to
both increases and decreases (Ebdrup et al., 2013). Wide-spread re-
ductions in cortical volumes in antipsychotic exposed monkeys (Dorph-
Petersen et al., 2005) compared to sham treatment were traced to result
from lower astrocyte number in the antipsychotic treated groups
(Konopaske et al., 2008). On the contrary, antipsychotic induced de-
crease in volume and thickness of anterior cingulate cortex in rats was
not associated to decrease in astrocyte number but instead to decrease
in neuropil (Vernon et al., 2014). Antipsychotics may also induce au-
tophagy, a process related to neurodegeneration and cell death, which
may contribute to volumetric changes (Shin et al., 2012).
4.3. Benzodiazepine use and brain volume change
Though the association of antipsychotic medication on structural
changes in the brain has gained considerable attention in the previous
years, the effects of benzodiazepines have not been taken into account.
In studies with over 2 year follow-ups looking at associations between
antipsychotics and brain MRI findings in schizophrenia only one used
benzodiazepine use as an exclusion criteria (Molina et al., 2005), 5
reported in their methods that subjects used also benzodiazepines
(Takahashi et al., 2012, 2011a, 2011b, 2010, 2009) and only one study
briefly discussed the potential confounding effect of benzodiazepine use
and need for further research on how benzodiazepines may affect brain
structures (Takahashi et al., 2010).
In our study, in the post hoc analysis regarding caudate volume
change, among those with low doses of both antipsychotics and ben-
zodiazepines the volume increased, whereas the decrease was largest
among those using both on high doses and the second largest when the
antipsychotic dose was low but the benzodiazepine dose was high.
Table 4.2
Associations between antipsychotic dose and benzodiazepine dose and brain structural
change during the follow-up and the statistically significant associations of antipsychotic
dose, benzodiazepine dose, PANSS average score and hospitalization days during the
follow-up in the same model. ICV and sex as covariates in all analyses. Statistically sig-
nificant (p< 0 05) findings are in bold.
Brain area CPZy BZDy CPZy, BZDy, PANSS and
hospitalization days in the same
model





b = -0.091 p = 0.716





b = -0.229 p = 0.283





b = -0.095 p = 0.702





b = -0.239 p = 0.271





b = 0.487 p = 0.035
BZDy
b = 0.037 p = 0.879





b = -0.350 p = 0.141










b = -0.153 p = 0.500
BZDy
b= -0.052 p = 0.832





b = -0.245 p = 0.214
hospitalization days b =-0.788
p<0.001





b = -0.072 p = 0.754
BZDy
b = -0.180 p = 0.468
CPZy = antipsychotic dose years in chlorpromazine equivalents during follow-up, BZDy
= benzodiazepine dose years in defined daily dose during follow-up, ICV= intracranial
volume, GM = grey matter, b= standardized beta, PANSS= The average score of
Positive and Negative Syndrome Scale (PANSS) total score at 34 years and 43 years, n.s.
= non-significant.
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Analysis of variance confirmed a significant main effect of benzodia-
zepine dose, with only a marginal effect of antipsychotic dose, and no
evidence of interaction. This suggests that the change in caudate nu-
cleus volume relates to benzodiazepine exposure rather than being
driven by an association with antipsychotic medication or any inter-
acting effect of these two medications. In summary, the effect of anti-
psychotics and benzodiazepines may be more additive than multi-
plicative.
The results of earlier CT studies on benzodiazepine effects on brain
structures are inconsistent, though the topic has not been studied ex-
tensively. The most recent studies on benzodiazepine effects on brain
structures detected by CT concluded that long-term benzodiazepine use
does not result in brain abnormalities (Busto et al., 2000; Lader et al.,
1984; Moodley et al., 1993; Perera et al., 1987). However, two studies
have found that benzodiazepines associate to increased ventricle-to-
brain ratio (Schmauss and Krieg, 1987; Uhde and Kellner, 1987) with
one even suggesting a dose-dependent effect (Schmauss and Krieg,
1987).
Long-term benzodiazepine use has been linked to cognitive dys-
function, and even after withdrawal patients may not return to the level
of cognition of matched controls without benzodiazepine use (Barker
et al., 2004b). A study of schizophrenia cases treated with second
generation antipsychotics found that after tapering off benzodiazepines
the cognitive performance improved significantly and there was also
improvement in quality of life and decrease in PANSS total scores
(Kitajima et al., 2012).
There is no current knowledge on the exact mechanism how ben-
zodiazepines could affect brain structures in humans. However, animal
studies have found that brain-derived neurotrophic factor (BDNF) levels
decreased after acute, but not repeated administration of the benzo-
diazepine triazolam and closely related drug zolpidem in the mouse
hippocampus (Licata et al., 2013b); that mice treated with benzodia-
zepines showed decrease in density of the spines of pyramidal neurons
(Curto et al., 2016) and diazepam reduced the level of transcripts in-
volved in synaptic functions and neural plasticity (Huopaniemi et al.,
2004). BDNF regulates neuronal connectivity and synaptic efficacy (Lu,
1999) and plays a key role in neural plasticity (Duman, 2004). Zol-
pidem has also found to alter the function of resting-state networks in
healthy individuals (Licata et al., 2013a), and functional aberration
often leads to structural changes as well (Keck et al., 2011). Since
benzodiazepine use has been associated with decline in cognition and
decreased structural plasticity in mice, there is a need for understanding
the mechanisms behind benzodiazepine effects on the brain at cellular
and macroscopic levels.
Knowing the potential effects and adverse effects benzodiazepines
may have on brain structure and functioning is essential in schizo-
phrenia, because the prevalence of benzodiazepine use varies from 15%
to even 91% (Mundt et al., 2012; Vares et al., 2011; Waterreus et al.,
2012). In NFBC1966, 42% of individuals with schizophrenia used
benzodiazepines at the age of 43 (Nykänen et al., 2016), and in our
study, 95% of patients had used benzodiazepines prior to study com-
mencement, with 79% using them in the inter-scan interval. Altogether,
in our sample, the use of benzodiazepines was extremely high, and this
is not supported by recent results on their possible harmful effects re-
garding e.g. mortality in schizophrenia (Fontanella et al., 2016) and
cognition (Baandrup et al., 2017). In addition, benzodiazepines are
commonly used in the general population: approximately 3% use ben-
zodiazepines over 6 months and in some populations the number is
even higher (Kurko et al., 2015). The fact that these medications are so
widely used underlines the importance of studying their long-term ef-
fects carefully.
4.4. Methodological discussion
This study partly demonstrates the importance of using adequate
covariates when studying variables that are sensitive to confounding
factors. Previous studies have not taken illness severity and potential
confounding medication into account comprehensively (Huhtaniska
et al., 2017). Taking illness related factors into account in this study
was also challenging, since the used variables correlated with each
other (see Supplement Table 6). When we examined the collinearity
between the variables used in our analyses, the degrees of multi-
collinearity was moderate and at an acceptable level to conduct the
analyses (see Supplement Tables 7 and 8 for details).
Imaging studies are often sensitive to confounding effects due to
various reasons. To exclude natural variation in brain volumes between
two time point images, the protocol before each scan should be as
strictly the same as possible, for example the diet and fluid intake
should be comparable. The scanner should be the same, it should not be
updated and phantoms should be imaged frequently for maximal
quality. Issues rising from these factors potentially confound the results
of imaging studies and though they are well-known, they are hard to
rule out when conducting longitudinal studies.
4.5. Strengths and limitations
A major strength of this study is the use of comprehensive,
thoroughly collected medication data. To our knowledge, there are
no other MRI studies with data on long-term longitudinal use of
both antipsychotics and benzodiazepines. Our data has been col-
lected using several sources: by interviewing the person themselves
and by scrutinizing all available medical records and collecting all
available information on prescribed doses and duration of treat-
ments.
Another strength is the rare naturalistic setting that is tailor-made
for studying long-term associations, effects and adverse effects of
medications (Wang et al., 2011). For example the observed wide range
in the used doses of both studied medications reflects the clinical rea-
lity. Naturalistic settings may provide novel information and perspec-
tive in contrast to clinical studies that are often made with determined
objectives and in more strictly selected study populations.
A limitation in our study is the sample size. Though there were 101
identified schizophrenia cases in the NFBC1966 in the beginning of this
study, only 73 of them participated at baseline and 45 at follow-up.
Possibly partly because of active home-recruitment in our study, the
participants did not differ from the non-participants in terms of age, sex
or educational level (Veijola et al., 2014). Still, we cannot be certain
this sample represents the whole schizophrenia population extensively
in all measured domains.
The small sample size limits the statistical power to find asso-
ciations, and due to several analyses performed some associations
may be due to chance. We did not correct for multiple comparisons
when analyzing different brain areas, since the size of brain struc-
tures are related to each other and a conservative correction
method (e.g. Bonferroni) would probably over-correct the results.
There were also some potential confounding factors that we were
unable to take into account in our analyses, such as other medica-
tion use, dietary profile or physical activity during the follow-up.
We tested whether alcohol use disorder affected the results, and
found no evidence that it did, but we could not control for alcohol
use as a continuous variable. In addition, we were unable to study
or control for the role of non-pharmacological therapies used, since
we do not have any data on possible psychosocial interventions.
One potential issue is using PANSS summary score as a covariate in
the analyses, since it is a sum based on original ordinal scale items.
Despite this, PANSS summary scores are commonly used in psy-
chiatric studies and analyses and therefore also used in this study as
a measure of illness severity. Given these facts, the results of this
study need to be interpreted cautiously and they need to be re-
plicated, especially regarding the findings on benzodiazepines.
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Another limitation is the uncertainty of how the scanner update
affects our measures of brain volumes. However, we tried to overcome
the possible interference by using test-retest measures. In any case, we
emphasize that the results of this study are only observed differences
between the MRI measures at two different time points and we do not
conclude a causal effect.
4.6. Conclusions
Higher cumulative antipsychotic dose associates to ventricular en-
largement in schizophrenia even after controlling for benzodiazepine
use and illness related factors. Nevertheless, we cannot be sure if an-
tipsychotics themselves cause the ventricular enlargement found in this
study as the use of antipsychotics may be a marker for a factor we are
unable to identify, which contributes to ventricular enlargement.
This study assessed the association between benzodiazepine use and
structural brain changes for the first time in schizophrenia, and sug-
gested an association with change in caudate volume. Our results sug-
gest that in the future, studies should focus also on benzodiazepine
effects on the brain and studies on antipsychotic effects should take
benzodiazepine use into account as a potential confounder.
There is a need for understanding the mechanisms behind anti-
psychotic and benzodiazepine related structural and functional changes
in the brain. Further studies should also focus on how medication re-
lated structural alterations correspond to cognition and functioning.
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